|
|
|
06 Oct 2007 |
Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
|
|
05 Oct 2007 |
Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial
|
|
03 Oct 2007 |
Protox completes BPH trial recruitment and announces positive interim data
|
|
02 Oct 2007 |
NicOx and Ferrer present promising clinical and preclinical
|
|
02 Oct 2007 |
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
|
|
02 Oct 2007 |
Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration
|
|
29 Sep 2007 |
Miglustat enters Phase IIa for Cystic Fibrosis
|
|
29 Sep 2007 |
Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Hyphanox(TM) for Onychomycosis
|
|
28 Sep 2007 |
MGI PHARMA Announces Submission of Aquavan(R) New Drug Application
|
|
28 Sep 2007 |
Palatin Technologies, Inc. Reports positive data from an at-home study of pre- and postmenopausal women with female sexual arousal disorder treated with bremelanotide
|
|
27 Sep 2007 |
ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
|
|
27 Sep 2007 |
JT and Torii Sign Licensing Agreement with Keryx for Development and Commercialization of Hyperphosphatemia Drug in Japan
|
|
27 Sep 2007 |
Recordati Successfully Ccompletes the Silodosin Double-Blind Phase III Study
|
|
27 Sep 2007 |
CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea
|
|
27 Sep 2007 |
Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX(TM)
|
|
25 Sep 2007 |
Q-Med obtains approval for MACROLANETM VRF in Europe
|
|
22 Sep 2007 |
ThromboGenics Completes Enrolment of Patients for the Vitreomacular Traction Trial (MIVI IIT)
|
|
20 Sep 2007 |
Depomed Completes Patient Enrollment in Phase 2 Trial for Gabapentin GR for the Treatment of Menopausal Hot Flashes
|
|
20 Sep 2007 |
Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
|
|
18 Sep 2007 |
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
|
|
14 Sep 2007 |
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
|
|
12 Sep 2007 |
Repros Therapeutics Announces U.S. IND for the Study of Proellex(R)
|
|
12 Sep 2007 |
Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
|
|
12 Sep 2007 |
Basilea Announces the Submissions of Marketing Authorization Applications in the EU for Alitretinoin, an Investigational Drug for the Treatment of Severe Refractory Chronic Hand Eczema
|
|
12 Sep 2007 |
Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
|
|
11 Sep 2007 |
Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
|
|
11 Sep 2007 |
First Ever Therapy Targets Optic Nerve Head for Glaucoma
|
|
11 Sep 2007 |
Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
|
|
11 Sep 2007 |
XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
|
|
07 Sep 2007 |
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
|
|
07 Sep 2007 |
The genes involved in rheumatoid arthritis identified
|
|
06 Sep 2007 |
Pieris validates the use of Anticalins(R) as ophthalmologic biotherapeutics
|
|
01 Sep 2007 |
ATL1103 for Growth & Sight Disorders Project Update
|
|
01 Sep 2007 |
BioDiem starts 4 new Monash studies with eye drug BDM-E
|
|
31 Aug 2007 |
Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
|
|
30 Aug 2007 |
King Pharmaceuticals And Palatin Technologies Delay Immediate Plans For Phase 3 Clinical Program With Bremelanotide For Erectile Dysfunction
|
|
29 Aug 2007 |
Orexo's treatment for incontinence/nocturia entering Phase I
|
|
29 Aug 2007 |
EPIX Pharmaceuticals Achieves Milestone in Collaboration with Cystic Fibrosis Foundation Therapeutics
|
|
29 Aug 2007 |
EPIX Pharmaceuticals Achieves Milestone iEPIX Pharmaceuticals Achieves Milestone in Collaboration with Cystic Fibrosis Foundation Therapeuticsn Collaboration with Cystic Fibrosis Foundation Therapeutics
|
|
29 Aug 2007 |
FDA Accepts for Review Complete Response to Approvable Letter for Entereg(R) (alvimopan) for POI
|
|
28 Aug 2007 |
Kythera Biopharmaceuticals initiates Phase II study of its adypolitic agent for reduction of submental fat
|
|
25 Aug 2007 |
Approval of an additional dosage and administration for secondary eradication of Helicobacter pylori for proton pump inhibitors in Japan
|
|
24 Aug 2007 |
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
|
|
24 Aug 2007 |
CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment of Erythema
|
|
23 Aug 2007 |
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
|
|
22 Aug 2007 |
BioMarin licenses technology from leading cystic fibrosis research laboratory at the University of California, San Francisco
|
|
18 Aug 2007 |
MediciNova reports Phase Ib clinical study results for MN-221, a novel treatment for preterm labor
|
|
18 Aug 2007 |
Anesiva receives FDA approval for Zingo(TM), a new, innovative product to reduce pain associated with needle insertion procedures in children
|
|
17 Aug 2007 |
Auxilium Pharmaceuticals, Inc. receives clearance to resume clinical trials for XIAFLEX(TM)
|
|
16 Aug 2007 |
Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease
|
| |
|
Results 401 - 450 of 985 |
